Medical Director of the Ray Dolby Brain Health Center, Chief of Memory for Sutter Health
January 22, 2026
Just three years ago, there were no FDA-approved treatments that targeted the underlying causes of Alzheimer’s—only medications that modified symptoms. Today, two FDA-approved therapies—Leqembi (lecanemab) and Kisunla (donanemab)—clear amyloid protein from the brain, targeting a potential cause of the disease. In this episode, a leading neurologist answers your most common questions about what these new therapies can realistically do, including effectiveness, safety, eligibility, infusion logistics, cost, and access.
BrightFocus Foundation is a premier global nonprofit funder of research to defeat Alzheimer’s, macular degeneration, and glaucoma. Since its inception more than 50 years ago, BrightFocus and its flagship research programs—Alzheimer’s Disease Research, Macular Degeneration Research, and National Glaucoma Research—has awarded more than $300 million in research grants to scientists around the world, catalyzing thousands of scientific breakthroughs, life-enhancing treatments, and diagnostic tools. We also share the latest research findings, expert information, and resources to empower the millions impacted by these devastating diseases. Learn more at brightfocus.org.
Disclaimer: The information provided here is a public service of BrightFocus Foundation and is not intended to constitute medical advice. Please consult your physician for personalized medical, dietary, and/or exercise advice. Any medications or supplements should only be taken under medical supervision. BrightFocus Foundation does not endorse any medical products or therapies.
Join Dr. Joshua Grill as he shares details about the AHEAD Study.
Join behavioral neurologist Dr. Marwan Sabbagh for an in-depth discussion about emerging Alzheimer’s therapeutics now in late-stage clinical development.
Join Dr. Beau Ances of Washington University in St. Louis to learn about the emerging science linking gut health and brain health.
Can everyday lifestyle choices really protect your memory? Dr. Laura Baker, professor at Wake Forest University School of Medicine, will share results from the groundbreaking U.S. POINTER trial—the largest study of its kind to test how lifestyle changes impact brain health.
Can light and sound help slow Alzheimer’s? Join Christian Howell, CEO of Cognito Therapeutics, as he shares the latest on the HOPE Study. Discover how non-invasive 40 Hz light and sound stimulation may protect memory, thinking, and daily function—and what’s next for this promising technology.
Every Donation is a Step Forward in the Fight Against Alzheimer’s
Your donation powers cutting-edge research and helps scientists explore new treatments. Help bring us closer to a cure and provide valuable information to the public.
Donate Today
